Company research
RAPID MICRO BIOSYSTEMS, INC.
CIK 1380106Updated Sep 27, 2026
SecurityRPID · NASDAQ · equity
Name history
RAPID MICRO BIOSYSTEMS INC · through Jul 15, 2009
RPID price & chart
Loading TradingView…
NASDAQ:RPID on TradingView ↗About the company
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered in Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @r…
In the news
Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results ↗
Recent filings
SCHEDULE 13G filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
4 filing
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 74,852,000Source | 98,169,000Source | 143,452,000Source | 190,650,000Source |
| Property, Plant and Equipment, NetUSD | 8,972,000Source | 11,193,000Source | 12,832,000Source | 13,818,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 20,030,000Source | 16,911,000Source | 24,285,000Source | 27,064,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 3,134,000Source | 7,519,000Source | 5,532,000Source | 5,369,000Source |
| Inventory, NetUSD | 17,593,000Source | 20,200,000Source | 19,961,000Source | 21,187,000Source |
| Assets, CurrentUSD | 61,168,000Source | 80,917,000Source | 120,415,000Source | 138,576,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,145,000Source | 2,466,000Source | 2,869,000Source | 3,372,000Source |
| Operating Lease, Right-of-Use AssetUSD | 3,981,000Source | 4,998,000Source | 5,972,000Source | 6,746,000Source |
| Other Assets, NoncurrentUSD | 319,000Source | 531,000Source | 770,000Source | 1,119,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 41,646,000Source | 22,817,000Source | 25,463,000Source | 26,481,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Additional Paid in CapitalUSD | 555,147,000Source | 550,157,000Source | 546,051,000Source | 540,775,000Source |
| Retained Earnings (Accumulated Deficit)USD | -522,397,000Source | -475,274,000Source | -428,385,000Source | -375,918,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 11,000Source | 39,000Source | -101,000Source | -1,109,000Source |
| Stockholders' Equity Attributable to ParentUSD | 33,206,000Source | 75,352,000Source | 117,989,000Source | 164,169,000Source |
| Liabilities and EquityUSD | 74,852,000Source | 98,169,000Source | 143,452,000Source | 190,650,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 18,487,000Source | 17,565,000Source | 18,986,000Source | 19,050,000Source |
| Operating Lease, Liability, CurrentUSD | 1,246,000Source | 1,167,000Source | 1,090,000Source | 729,000Source |
| Accounts Payable, CurrentUSD | 4,139,000Source | 2,535,000Source | 1,973,000Source | 5,428,000Source |
| Operating Lease, Liability, NoncurrentUSD | 3,539,000Source | 4,784,000Source | 5,952,000Source | 6,898,000Source |
| Other Liabilities, NoncurrentUSD | 397,000Source | 298,000Source | 263,000Source | 229,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 8,316,000Source | 7,217,000Source | 9,907,000Source | 8,150,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 18,902,000Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 3,252,000Source | 3,362,000Source | 3,105,000Source | 2,837,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 4,033,000Source | 3,874,000Source | 4,750,000Source | 4,019,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -4,387,000Source | 1,987,000Source | 163,000Source | 364,000Source |
| Increase (Decrease) in InventoriesUSD | -1,465,000Source | 335,000Source | -1,193,000Source | 5,843,000Source |
| Increase (Decrease) in Accounts PayableUSD | 1,600,000Source | 562,000Source | -3,455,000Source | 1,484,000Source |
| Deferred Income Tax Expense (Benefit)USD | 11,423,000Source | 11,494,000Source | -12,418,000Source | -16,171,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -31,062,000Source | -44,153,000Source | -45,081,000Source | -58,547,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 14,329,000Source | 36,657,000Source | 42,153,000Source | -93,469,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 850,000Source | 1,365,000Source | 1,845,000Source | 6,740,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 419,000Source | — | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 19,771,000Source | 203,000Source | 149,000Source | 693,000Source |
| Repayments of Long-term DebtUSD | — | — | — | 0Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 20,314,000Source | 17,276,000Source | 24,569,000Source | 27,348,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 770,000Source | 40,000Source | 38,000Source | 42,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 4,033,000Source | 3,874,000Source | 4,750,000Source | 4,019,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | 0Source |
| Capitalized Computer Software, AmortizationUSD | 500,000Source | 400,000Source | 300,000Source | 300,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | 0Source | -28,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | 0Source |
| General and Administrative ExpenseUSD | 22,754,000Source | 21,947,000Source | 24,936,000Source | 26,819,000Source |
| Income Tax Expense (Benefit)USD | 40,000Source | 22,000Source | 31,000Source | -576,000Source |
| InterestExpenseNonoperatingUSD | 1,090,000Source | — | — | — |
| Inventory Write-downUSD | 1,143,000Source | 95,000Source | 34,000Source | 326,000Source |
| Investment Income, InterestUSD | 1,509,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -47,123,000Source | -46,889,000Source | -52,467,000Source | -60,806,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -60,806,000Source |
| Nonoperating Income (Expense)USD | 309,000Source | 3,052,000Source | 4,127,000Source | 1,837,000Source |
| Other Nonoperating Income (Expense)USD | -110,000Source | -112,000Source | -83,000Source | 59,000Source |
| Proceeds from Issuance of Common StockUSD | 445,000Source | — | — | — |
| Proceeds from Issuance of Long-term DebtUSD | 20,000,000Source | — | — | — |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | 39,750,000Source | 69,100,000Source | 106,490,000Source | 92,500,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 33,587,000Source | 28,051,000Source | 22,519,000Source | 17,133,000Source |
| Operating Income (Loss)USD | -47,392,000Source | -49,919,000Source | -56,563,000Source | -63,219,000Source |
| Other Nonoperating Income (Expense)USD | -110,000Source | -112,000Source | -83,000Source | 59,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -47,083,000Source | -46,867,000Source | -52,436,000Source | -61,382,000Source |
| Income Tax Expense (Benefit)USD | 40,000Source | 22,000Source | 31,000Source | -576,000Source |
| Net Income (Loss) Attributable to ParentUSD | -47,123,000Source | -46,889,000Source | -52,467,000Source | -60,806,000Source |
| Earnings Per Share, BasicUSD per share | -1.05Source | -1.08Source | -1.22Source | -1.43Source |
| Earnings Per Share, DilutedUSD per share | -1.05Source | -1.08Source | -1.22Source | -1.43Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 44,679,341Source | 43,575,705Source | 43,024,039Source | 42,454,403Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 44,679,341Source | 43,575,705Source | 43,024,039Source | 42,454,403Source |
| Interest Expense (non-operating)USD | 1,090,000Source | — | — | — |
| Additional Financial Items | ||||
| Capitalized Computer Software, AmortizationUSD | 500,000Source | 400,000Source | 300,000Source | 300,000Source |
| Cost, Depreciation and AmortizationUSD | 2,800,000Source | 2,900,000Source | 2,700,000Source | 2,500,000Source |
| Costs and ExpensesUSD | 80,979,000Source | 77,970,000Source | 79,082,000Source | 80,352,000Source |
| Current Income Tax Expense (Benefit)USD | 40,000Source | 22,000Source | 31,000Source | -576,000Source |
| General and Administrative ExpenseUSD | 22,754,000Source | 21,947,000Source | 24,936,000Source | 26,819,000Source |
| Income (Loss) Attributable to Parent, before TaxUSD | -47,083,000Source | -46,867,000Source | -52,436,000Source | -61,382,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -47,105,000Source | -46,872,000Source | -52,455,000Source | -61,396,000Source |
| Interest Income (Expense), NetUSD | — | — | 4,210,000Source | 1,778,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | 3,164,000Source | — | — |
| Investment Income, InterestUSD | 1,509,000Source | — | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -60,806,000Source |
| Nonoperating Income (Expense)USD | 309,000Source | 3,052,000Source | 4,127,000Source | 1,837,000Source |
| Research and Development ExpenseUSD | 13,603,000Source | 14,597,000Source | 12,820,000Source | 12,866,000Source |
| Selling and Marketing ExpenseUSD | 12,082,000Source | 13,266,000Source | 13,322,000Source | 14,994,000Source |
Filing attachments
tm2614922d1_ex4-1.htm · 8-K · 2026-05-19
EX-4.1 3 tm2614922d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 RAPID MICRO BIOSYSTEMS, INC. WARRANT TO PURCHASE COMMON STOCK Number of Shares: [_________] (subject to adjustment) Warrant No. PFW-[ ] Original Issue Date: May [ ], 2026 ─────────────────────────────────────────────────────────────── Rapid Micro Biosystems, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, […
Read attachment ↗tm2614922d1_ex4-2.htm · 8-K · 2026-05-19
EX-4.2 4 tm2614922d1_ex4-2.htm EXHIBIT 4.2 Exhibit 4.2 RAPID MICRO BIOSYSTEMS, INC. WARRANT TO PURCHASE COMMON STOCK OR PRE-FUNDED WARRANTS Number of Shares: [_________] (subject to adjustment) Warrant No. CW-[___] Original Issue Date: May [___], 2026 ────────────────────────────────────────────────────────────────── Rapid Micro Biosystems, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of whi…
Read attachment ↗tm2614922d1_ex4-3.htm · 8-K · 2026-05-19
EX-4.3 5 tm2614922d1_ex4-3.htm EXHIBIT 4.3 Exhibit 4.3 RAPID MICRO BIOSYSTEMS, INC. WARRANT TO PURCHASE COMMON STOCK OR PRE-FUNDED WARRANTS Number of Shares: [_________] (subject to adjustment) Warrant No. CW-[___] Original Issue Date: May [___], 2026 ────────────────────────────────────────────────────────────────── Rapid Micro Biosystems, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of whi…
Read attachment ↗ex-991_rpidx12312025.htm · 8-K · 2026-03-12
EX-99.1 2 ex-991_rpidx12312025.htm EX-99.1 Document Exhibit 99.1 Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance • Reports record fourth quarter 2025 total revenue of $11.3 million, representing 37% growth compared to fourth quarter 2024 • Reports full year 2025 total revenue of $33.6 million, representing 20% growth compared to 2024 • Amgen expands global Growth Direct system rollout with significant multi-system orde…
Read attachment ↗ex-992_rpidx20260312.htm · 8-K · 2026-03-12
EX-99.2 3 ex-992_rpidx20260312.htm EX-99.2 Document Exhibit 99.2 Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct ® Platform Companies deepen partnership to advance automated, integrated microbiology quality control Lexington, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation sol…
Read attachment ↗ex-991_prx20260113.htm · 8-K · 2026-01-13
EX-99.1 2 ex-991_prx20260113.htm EX-99.1 Document Rapid Micro Biosystems Announces Record Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue • Fourth quarter 2025 total revenue expected to be approximately $11.3 million, representing growth of approximately 37% compared to the prior-year period. • Received record multi-system order in the fourth quarter from an existing Top 20 global biopharma customer to automate global manufacturing network. • Full year 2025 total revenue…
Read attachment ↗